熱門資訊> 正文
Monte Rosa强调更新后的1/2期数据显示，在重度预治疗的mCRPC中，RECIST总体疾病控制率和肿瘤减少率为67%
2026-02-24 20:19
- In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reduction in size of target lesions
- Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions
- Combination of MRT-2359 and enzalutamide was generally well-tolerated with primarily Grade 1-2 adverse events (AEs); no treatment discontinuations due to AEs
- Company plans to initiate a new, signal-confirming Phase 2 study of MRT-2359 targeting AR mutant patients in Q3 2026
推薦文章
提價83%需求卻暴增400%！智譜、MiniMax鎖定大模型定價權，AI Agent元年即將開啟？
港股見底了嗎？北水大舉加倉逾600億港元！大行看好4月做多窗口來臨，十大金股一圖睇全
華盛早報 | 伊朗與阿曼擬共管霍爾木茲！美股V型反轉；伊朗襲擊甲骨文、亞馬遜數據中心；港美股今日因假期休市一天
諾和諾德稱：口服版Wegovy減肥效果優於禮來GLP‑1口服藥
美股機會日報 | 特朗普粉碎停戰幻想！恐慌指數飆升12%，納指期貨跌約2%；美油期貨暴漲超9%！油氣股飆升，美國原油基金ETF漲超9%
清明休市提醒 | 港股本周五休市，下周三恢復交易；美股周五休市一天
油價上漲 此前特朗普表示伊朗衝突可能在未來幾周升級
野村：特朗普講話未能發出局勢降温的明確信號
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
